Evidence map›Paper›PMID 18667507›Full record

ArticleJournal of virology2008

Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.

Shuji Sato, Eloisa Yuste, William A Lauer, Eun Hyuk Chang, Jennifer S Morgan, Jacqueline G Bixby, Jeffrey D Lifson, Ronald C Desrosiers, Welkin E Johnson

Abstract read
In one paragraph

Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 25 citations in OpenAlex.

  1. Molecular therapy. Advances · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Journal of virology · 2018
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Functional contributions of carbohydrate on AIDS virus glycoprotein.The Yale journal of biology and medicine · 2010
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shuji SatoNew England Primate Research Center, Department of Microbiology and Molecular Genetics, Harvard Medical School, Southborough, MA 01772, USA.
Eloisa Yuste
William A Lauer
Eun Hyuk Chang
Jennifer S Morgan
Jacqueline G Bixby
Jeffrey D Lifson
Ronald C Desrosiers
Welkin E Johnson
Harvard University · USNew England Biolabs (United States) · USScience Applications International Corporation (United States) · US

Funding

ZETA CHAIN OF T CELL RECEPTOR INTERACTS W/ NEF OF SIV &HIV2P51RR000168 · NCRR · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JOHNSON, R. PAUL · 1985 to 2011
$139.3M
MOLECULAR BASIS FOR STV PATHOGENICITYR37AI025328 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI DESROSIERS, RONALD C · 1996 to 2005
$2.5M
MOLECULAR BASIS FOR SIV PATHOGENICITYR01AI025328 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI DESROSIERS, RONALD C · 1987 to 2010
$2.0M
Replication and Persistence of Primate LentivirusesR01AI057039 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JOHNSON, WELKIN E · 2003 to 2009
$1.9M
MOUSE MODELS OF CANCER, BONE DISEASE, AND LACTATIONK26RR000168 · NCRR · OHIO STATE UNIVERSITY · PI ROSOL, THOMAS J · 2000 to 2004
$547k
NCI NIH HHS N01-CO-124000NCRR NIH HHS K26 RR000168NCRR NIH HHS P51 RR000168NCRR NIH HHS RR00168NIAID NIH HHS AI057039NIAID NIH HHS AI25328NIAID NIH HHS R01 AI025328NIAID NIH HHS R01 AI057039NIAID NIH HHS R37 AI025328
6 · The paper itself

Abstract

Here, we describe the evolution of antigenic escape variants in a rhesus macaque that developed unusually high neutralizing antibody titers to SIVmac239. By 42 weeks postinfection, 50% neutralization of SIVmac239 was achieved with plasma dilutions of 1:1,000. Testing of purified immunoglobulin confirmed that the neutralizing activity was antibody mediated. Despite the potency of the neutralizing antibody response, the animal displayed a typical viral load profile and progressed to terminal AIDS with a normal time course. Viral envelope sequences from week 16 and week 42 plasma contained an excess of nonsynonymous substitutions, predominantly in V1 and V4, including individual sites with ratios of nonsynonymous to synonymous substitution rates (dN/dS) highly suggestive of strong positive selection. Recombinant viruses encoding envelope sequences isolated from these time points remained resistant to neutralization by all longitudinal plasma samples, revealing the failure of the animal to mount secondary responses to the escaped variants. Substitutions at two sites with significant dN/dS values, one in V1 and one in V4, were independently sufficient to confer nearly complete resistance to neutralization. Substitutions at three additional sites, one in V4 and two in gp41, conferred moderate to high levels of resistance when tested individually. All the amino acid changes leading to escape resulted from single nucleotide substitutions. The observation that antigenic escape resulted from individual, single amino acid replacements at sites well separated in current structural models of Env indicates that the virus can utilize multiple independent pathways to rapidly achieve similar levels of resistance.

Indexed as

AnimalsAntibodiesAntibodies, ViralAntigensEnzyme-Linked Immunosorbent AssayImmunoglobulin GMacaca mulattaNeutralization TestsNucleotidesPeptidesRNA, ViralSimian Immunodeficiency VirusTime FactorsViral Envelope ProteinsVirus ReplicationAntibodiesAntibodies, ViralAntigensImmunoglobulin GNucleotidesPeptidesRNA, ViralViral Envelope Proteins

Identifiers

PMID18667507
PMCPMC2546989
OpenAlexW2133160469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.